Clin2
NCT06559306Possibly a fitRecruiting

Seltorexant for depression with insomnia symptoms

Depressive Disorder, Major

Part of Mental health clinical trials.

This trial tests if adding seltorexant to your current antidepressant can improve depression and sleep problems. It is for people with major depressive disorder who still have symptoms, especially insomnia, despite trying at least one antidepressant.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
752 people
Ages
18 years to 74 years
Study type
Interventional

Who can take part

  • You must have a diagnosis of major depressive disorder (without psychosis) that started before age 60.
  • You must have tried at least one but no more than two antidepressants for your current depression, and they did not work well enough.
  • You must be currently taking and tolerating one of these antidepressants at a stable dose for the past 6 weeks: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine.
  • Your depression must be at least moderately severe, with significant insomnia symptoms, and not have improved too much during screening.
  • You must not have serious medical conditions like kidney failure, unstable heart disease, uncontrolled diabetes, narcolepsy, seizures, or thyroid problems.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07573176Recruiting· Phase 3
Seltorexant for Depression in Adults and Older Adults

This study tests a new medication called seltorexant as a standalone treatment for major depression. The trial is for adults and older adults who have depression that hasn't improved with other antidepressants or who haven't tried them yet.

Bryant, Arkansas
NCT06633016Recruiting· Phase 2
ABX-002 for major depression (add-on treatment)

This trial tests a new medication called ABX-002 as an add-on to your current antidepressant. It's for people with moderate to severe depression who haven't gotten enough help from their current antidepressant alone.

Birmingham, Alabama
NCT06547489Recruiting· Phase 2
Testing zelquistinel for major depression

This study tests whether zelquistinel, an investigational drug, can reduce symptoms of major depressive disorder (a type of clinical depression). It is for people who are currently experiencing a moderate to severe depressive episode and are not taking other antidepressants.

Birmingham, Alabama
NCT07555743Not yet recruiting· Phase 4
New Insomnia Treatment for Depression Patients

This study tests whether a new sleep medication called daridorexant helps people with depression who also struggle with insomnia. You would take this medication for several weeks while researchers track how it affects your sleep and mood.

Barcelona, Catalonia
NCT06827431Not yet recruiting· Phase 3
Testing ammoxetine for depression

This trial tests an investigational medication called ammoxetine for people with moderate to severe depression. It aims to see if the drug can reduce depressive symptoms and is for those who haven't had success with certain other antidepressants.

NCT05641623Recruiting· Phase 2
Study drug for depression that didn’t improve on common antidepressants

This Phase 2 trial tests OSU6162 added to an SSRI or SNRI in people whose major depression did not improve enough after trying specific antidepressants for at least 6 weeks. It may help reduce depression symptoms when standard treatments haven’t worked well.

Lund, Skåne County

Hear when a new Depressive Disorder, Major trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.